Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy

Endocrine Practice

Volumn 13, Issue 4, 2007, Pages 396-402

  Vilar, Lucio ^a   Czepielewsk, Mauro A ^b   Naves, Luciana Ansaneli ^c   Rollin, Guilherme A F S ^b   Casulari, Luiz Augusto ^c   Coelho, Carlos E ^d  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CABERGOLINE; ERGOLINE DERIVATIVE;

ACROMEGALY; ADENOMA; ADULT; ARTICLE; CASE REPORT; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS TUMOR; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROLACTINOMA;

ACROMEGALY; ADENOMA; ADULT; ANTINEOPLASTIC AGENTS; ERGOLINES; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA;

EID: 34548462041     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.4.396     Document Type: Article

References (50)

1. Ayuk J, Sheppard MC. Growth hormone and its disorders. Postgrad Med J. 2006;82:24-30.
2. Kovacs K, Horvath E. Pathology of pituitary tumors. Endocrinol Metab Clin North Am. 1987;16:529-551.
3. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med. 1993;86:293-299.
4. Katznelson L. Diagnosis and treatment of acromegaly. Growth Horm IGF Res. 2005;15(Suppl A):S31-S35.
5. Roelfsema F, Biermasz NR, Romijn JA, Pereira AM. Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005;10:875-890.
6. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab. 2002;87:4054-4058.
7. Laws ER, Vance ML, Thapar K. Pituitary surgery for the management of acromegaly. Horm Res. 2000;53(Suppl 3):71-75.
8. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical "cure." Eur J Endocrinol. 2005;152: 379-387.
9. Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER. Treatment outcomes and mortality of 94 patients with acromegaly [with discussion]. Acta Neurochir (Wien). 2005;147:243-251.
10. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf). 2003;58:86-91.
11. De P, Rees DA, Davies N, et al. Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab. 2002;88:3567-3572.
12. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999;50:561-567.
13. Sheaves R, Jenkins P, Blackburn P, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf). 1996;45:407-413.
14. Jenkins D, O'Brien I, Johnson A, Shakespear R, Sheppard MC, Stewart PM. The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clin Endocrinol (Oxf). 1995;43:517-522.
15. Vilar L, Naves L, Freitas MC, Oliveira S, Leite V, Canadas V. Medical treatment of pituitary tumors-part I: prolactinomas and GH secreting adenomas. Arq Bras Endocrinol Metab. 2000;44:367-381.
16. Donangelo I, Melmed S. Treatment of acromegaly: future. Endocrine. 2005;28:123-128.
17. Ezzat S. Pharmacological options in the treatment of acromegaly. Curr Opin Investig Drugs. 2005;6:1023-1027.
18. Ayuk J, Stewart SE, Stewart PM, Sheppard MC (European Sandostatin LAR Group). Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf). 2004;60:375-381.
19. Taboada GF, van Haute FR, Correa LL, Casini AF, Gadelha MR. Etiologic aspects and management of acromegaly. Arq Bras Endocrinol Metab. 2005;49:626-640.
20. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88:3090-3098.
21. Freda PU. How effective are current therapies for acromegaly? Growth Horm IGF Res. 2003;13(Suppl A):S144-S151.
22. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87:3013-3018.
23. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992;21:713-735.
24. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study of 64 patients. J Clin Endocrinol Metab. 1998;83:374-378.
25. Cozzi R, Attanasio R, Barausse M, et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol. 1998;139:516-521.
26. Jackson SN, Fowler J, Howlett TA. Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol (Oxf). 1997;46:745-749.
27. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary. 2004;7:21-30.
28. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest. 1997;20:537-546.
29. Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 1997;82:518-523.
30. Vilar L, Naves L, Oliveira S, Lyra R. Cabergoline efficacy in the management of acromegaly. Arq Bras Endocrinol Metab. 2002;46:269-274.
31. Paisley AN, Trainer P, Drake W. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. Expert Opin Biol Ther. 2004;4:421-425.
32. Paisley AN, Drake WM. Treatment of pituitary tumors: pegvisomant. Endocrine. 2005;28:111-114.
33. Rains CP, Bryson HM, Fitton A. Cabergoline: a review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs. 1995;49:255-279.
34. Colao A, Lombardi G, Annunziato L. Cabergoline. Expert Opin Pharmacother. 2000;1:555-574.
35. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518-2522.
36. Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000;85:2247-2252.
37. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (Cabergoline Comparative Study Group). A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1994;331:904-909.
38. Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82:876-883.
39. Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997;82: 3574-3579.
40. Di Chirio G, Nelson KB. The volume of the sella turcica. Am J Roentgenol Radium Ther Nucl Med. 1962;87:989-1008.
41. Marzullo P, Ferone D, Di Somma C, et al. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary. 1999;1:115-120.
42. Maheshwari HG, Prezant TR, Herman-Bonert V, Shahinian H, Kovacs K, Melmed S. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J Clin Endocrinol Metab. 1997;85:3409-3416.
43. Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to longacting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005;152:569-574.
44. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004;61:209-215.
45. Saeger W. Current pathological classification of pituitary adenomas. Acta Neurochir Suppl. 1996;65:1-3.
46. Rickels MR, Snyder PJ. Cabergoline decreases somatotroph adenoma size: a case report. Pituitary. 2004;7:107-110.
47. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90:4465-4473.
48. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005;90: 4405-4410.
49. Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf). 2005;63:168-175.
50. Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf). 2006;64:342-351.